
Chiesi launches European and US venture fund
Italian pharmaceutical company Chiesi Group has launched a joint venture fund in collaboration with US-based venture investor AM Pappas & Associates, targeting assets in Europe and the US.
The fund, Chiesi Ventures, will focus on early-stage companies within the rare disease therapies market.
AM Pappas was selected to manage the fund as a result of the VC's track record investing in companies that develop therapies for orphan and rare diseases.
Chiesi will have offices in Boston, The Research Triangle Park in North Carolina and Parma, Italy, where Chiesi is headquartered.
The vehicle is also intended to serve as a platform for expanding Chiesi's networking activities with US universities, investors and rare disease patient organisations.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater